Pier Paolo Di Domenico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pier Paolo Di Domenico has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cosimo Di Raimondo
Dermatology Unit, Fondazione Policlinico “Tor Vergata”, 00133 Rome, Italy
2 shared publications - Flavia Lozzi
Department of Dermatology, University of Roma Tor Vergata, 00133 Rome, Italy
2 shared publications - Luca Bianchi
Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
2 shared publications - Claudia Paganini
Department of Systems Medicine University of Rome “Tor Vergata” Rome Italy
1 shared publication - Elena Campione
Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
1 shared publication - Elena Campione
Dermatology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 28 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7099
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the overlap in clinical and histological features with a large spectrum of inflammatory and neoplastic diseases, BPDCN is difficult to diagnose. Furthermore, given the rarity of the disease, treatment options for BPDCN are limited, sometimes changing by practitioner and hospitals. Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN.
- 28 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7099
Open AccessBlastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the overlap in clinical and histological features with a large spectrum of inflammatory and neoplastic diseases, BPDCN is difficult to diagnose. Furthermore, given the rarity of the disease, treatment options for BPDCN are limited, sometimes changing by practitioner and hospitals. Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN.
- Open Access
- 26 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14535
The Diagnosis and Management of Cutaneous Metastases from Melanoma
Melanoma is one of the deadliest skin tumors, accounting for almost 90% of skin cancer mortality. Although immune therapy and targeted therapy have dramatically changed the prognosis of metastatic melanoma, many patients experience disease progression despite the currently available new treatments. Skin metastases from melanoma represent a relatively common event as first sign of advanced disease or a sign of recurrence. Skin metastases are usually asymptomatic, although in advanced stages, they can present with ulceration, bleeding, and superinfection; furthermore, they can cause symptoms related to compression on nearby tissues. Treatments vary from simple surgery resections to topical or intralesional local injections, or a combination of these techniques with the most recent systemic immune or target therapies. New research and studies should focus on the pathogenesis and molecular mechanisms of the cutaneous metastases of melanoma in order to shed light on the mechanisms underlying the different behavior and prognoses of different patients.
- 26 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14535
Open AccessThe Diagnosis and Management of Cutaneous Metastases from Melanoma
Melanoma is one of the deadliest skin tumors, accounting for almost 90% of skin cancer mortality. Although immune therapy and targeted therapy have dramatically changed the prognosis of metastatic melanoma, many patients experience disease progression despite the currently available new treatments. Skin metastases from melanoma represent a relatively common event as first sign of advanced disease or a sign of recurrence. Skin metastases are usually asymptomatic, although in advanced stages, they can present with ulceration, bleeding, and superinfection; furthermore, they can cause symptoms related to compression on nearby tissues. Treatments vary from simple surgery resections to topical or intralesional local injections, or a combination of these techniques with the most recent systemic immune or target therapies. New research and studies should focus on the pathogenesis and molecular mechanisms of the cutaneous metastases of melanoma in order to shed light on the mechanisms underlying the different behavior and prognoses of different patients.